Related Party Transactions (Details) - USD ($) $ in Thousands |
1 Months Ended | 3 Months Ended | |||||
|---|---|---|---|---|---|---|---|
Aug. 26, 2021 |
Feb. 16, 2021 |
Aug. 31, 2021 |
Jun. 30, 2018 |
Mar. 31, 2026 |
Mar. 31, 2025 |
Dec. 31, 2025 |
|
| Related Party Transaction [Line Items] | |||||||
| Common stock, shares issued (in shares) | 222,019,108 | 193,000,611 | |||||
| Accounts payable | $ 5,082 | $ 5,404 | |||||
| Accrued expenses | 8,677 | 10,540 | |||||
| Fresenius Medical Care | |||||||
| Related Party Transaction [Line Items] | |||||||
| Accounts payable | 200 | 200 | |||||
| Fresenius Medical Care | Fresenius Medical Care | |||||||
| Related Party Transaction [Line Items] | |||||||
| Financing transaction | $ 150,000 | ||||||
| Conversion of stock (in shares) | 15,812,735 | ||||||
| Proceeds from PIPE financing | $ 25,000 | ||||||
| Common stock, shares issued (in shares) | 2,500,000 | ||||||
| Distribution agreement, termination period | 12 months | ||||||
| Fresenius Medical Care | Fresenius Medical Care Deutschland GmbH | |||||||
| Related Party Transaction [Line Items] | |||||||
| Clinical research services expense | 0 | $ 0 | |||||
| Accounts payable | $ 0 | $ 0 | |||||
| X | ||||||||||
- Definition Clinical Research Services Expense No definition available.
|
| X | ||||||||||
- Definition Distribution Agreement, Termination Period No definition available.
|
| X | ||||||||||
- Definition Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|